World first study of novel antibody therapeutic in peanut allergic individuals using the proprietary SEQ SIFTER™ antibody discovery platform now fully enrolled SOUTH SAN FRANCISCO, Calif.--(BUSINESS ...
There is no recent news for this security. Got a confidential news tip? We want to hear from you. Sign up for free newsletters and get more CNBC delivered to your inbox Get this delivered to your ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results